Integrin-associated protein (IAP/CD47) is a 50 kDa transmembrane protein initially defined as a regulator of β 3 integrin-mediated functions in neutrophils. IAP also can synergize with the TCR in T cell activation independent of β 3 integrins. To analyze the mechanism for IAP synergy with TCR, we expressed in Jurkat cells a chimeric molecule, consisting of the CD16 extracellular domain, the CD7 transmembrane domain and the TCR ζ chain cytoplasmic tail (CD16-7-ζ), which on its own is unable to induce IL-2 production. Ligation of IAP acted in synergy with TCR to induce IL-2 transcription and synthesis, but failed to synergize with the signal generated by CD16-7-ζ, while CD28 was a potent co-stimulator with both TCR and CD16-7-ζ. The failure of IAP to activate Jurkat together with CD16-7-ζ correlated with a lack of c-Jun N-terminal kinase, but not extracellularsignal-regulated kinase activation. Jurkat adhesion to anti-IAP, but not anti-CD28, induced cell spreading and the same domains of IAP required for augmentation of T cell activation were required to induce cell spreading. IAP synergy with TCR signaling likely results from its ability to stimulate adhesion to a ligand-expressing surface or antigen-presenting cell (APC), rather than from initiation of a novel signaling cascade. We conclude that a major role for ligation of IAP in T cell activation is to enhance the efficiency of TCR signaling by causing T cells to spread on an APC or surface.
Introduction
Activation of T lymphocytes from a quiescent to a proliferating state requires not only the engagement of the TCR complex but also the participation of accessory or co-stimulatory molecules (1) (2) (3) . Lack of co-stimulation prevents cytokine production and clonal expansion, and can induce a state of unresponsiveness or anergy (2, 4) . CD28 is a well-described co-stimulatory molecule, which contributes to T cell activation by inducing the activation of signaling events that do not occur when TCR is ligated alone (3, 5) . The ability of CD28-deficient T cells to develop normally (6) suggests that there may be other T cell surface molecules that can, in some circumstances, serve the same co-stimulatory function as CD28.
mechanism of IAP synergy with TCR signaling and compared it to CD28 co-stimulation.
IAP is a 50 kDa protein, which has three domains: an Ig variable (IgV)-like N-terminal domain, a domain containing multiple membrane-spanning segments and a short cytoplasmic tail with four alternatively spliced forms (14, 15) . IAP was identified by co-immunoprecipitation with β 3 integrins (16) and later shown to be identical to the erythrocyte antigen CD47 (17, 18) . IAP has a role in several β 3 -mediated functions, such as binding of vitronectin-coated beads to cells expressing α v β 3 (19) , polymorphoneutrophil activation by and chemotaxis to Arg-Gly-Asp (RGD)-containing ligands (20) , and an increase in intracellular [Ca 2ϩ ] in endothelial cells during adhesion to fibronectin (21) , as shown by both antibody inhibition and genetic analysis. IAP is more broadly expressed than α v β 3 , suggesting it may have additional physiologic functions. This is supported by the finding that IAP's role as an accessory molecule in T cell proliferation appears to be independent of its association with β 3 (11, 12) .
To analyze the mechanism of synergy between the TCR complex and IAP, we simplified the TCR by substitution with a chimeric molecule consisting of the CD16 extracellular domain, the CD7 transmembrane domain and the TCR ζ chain cytoplasmic tail (16-7-ζ) . Previous studies have shown that this chimera is sufficient to induce T cell activation events, such as an increase in [Ca 2ϩ ] i and induction of cytolytic activity (26) . CD28, but not IAP, was able to synergize with 16-7-ζ to activate IL-2 synthesis and stimulate N-terminal jun kinase (JNK) in Jurkat cells. In contrast, adhesion of Jurkat cells to surfaces coated with anti-IAP, but not anti-CD28 mAb, induced cell spreading. These data suggest that ligation of IAP results in increased interaction of adherent cells with the antigen-presenting surface, thereby enhancing the efficiency of TCR signaling, but is unable to confer new signaling capability on the TCR. This mechanism for augmenting TCR signaling is completely distinct from CD28, but may be shared by other receptors which synergize with TCR through adhesion.
Methods

Cell culture
Jurkat and the IAP-deficient Jurkat clone JinB8 were maintained in culture in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 0.1 mM NEAA, 50 µM 2-mercaptoethanol and 0.1% gentamicin. Transfected Jurkat were maintained in the same media in the presence of 1.5 mg/ml geneticin (Gibco/ BRL, Gaithersburg, MD). Cells were cloned by limiting dilution.
Generation of IAP-deficient Jurkat cells
The Jurkat T cell line was obtained from the ATCC (Rockville, MD). Briefly, Jurkat cells were cultured at a concentration of 0.5ϫ10 6 cells/ml in RPMI medium supplemented with 10% FCS. Ethyl-methanesulfonate (200 µg/ml) (Sigma, St Louis, MO) was added for 18 h. Cells were washed 3 times and allowed to recover for 5 days. IAP-expressing cells were eliminated by seven rounds of negative selection using the mAb BRIC126 (1 µg/ml) (International Blood Group Reference Laboratory, Bristol, UK) and non-toxic rabbit complement (Behring, Marburg, Germany). Finally, cells were labeled with BRIC126 and stained with FITC-rabbit anti-mouse F(abЈ) 2 , and IAP -cells were sorted using FACS sorting (FACStar; Becton Dickinson, Mountain View, CA).
DNA constructs
Standard techniques were used for nucleic acid manipulations. The CD16-7-ζ construct was a kind gift of Dr Brian Seed (Harvard Medical School, Boston, MA). The cDNA was subcloned into pRC/CMV using HindIII and NotI sites. To generate the epitope tagged FLAG-TM2 construct, the following oligonucleotides containing the FLAG sequence were made: 5Ј-AACAGCTAGCGGACTACAAAGACGATGACGATA-AGAGATC-3Ј and 5Ј-GTGGATCCGCAGATCTCTTATCGTCAT-CGTCTTTGTAGTC-3Ј, which include a BamHI and NheI site. The primers were allowed to anneal, and the annealed product was cut with BamHI and NheI. The purified fragment was then ligated into pIAP401 cut with BamHI and NheI, which contains the CD5 signal sequence 5Ј of the BamHI site (kind gift from Dr Brian Seed), generating pIAP332. The XhoI-BamHI fragment of pIAP332 containing the CD5 signal sequence 5Ј of the FLAG sequence was ligated together with a BamHINhe1 fragment from pIAP331 encoding the IAP transmembrane domain and form 2 tail into pBRSRaEN cut with XhoI and XbaI.
DNA Transfection cDNA constructs were transfected into wild-type Jurkat clones or the IAP-deficient Jurkat clone JinB8 by electroporation. For stable transfections, Jurkat clones (5ϫ10 6 /500 µl) were mixed with 15 µg cut plasmid DNA in fresh RPMI medium, incubated at room temperature for 10 min and then electroporated at 300 V, 1000 µF in a 0.4 cm cuvette using the Invitrogen Electroporator II. After electroporation, cells were immediately placed on ice for 10 min and then resuspended in 10 ml RPMI complete medium for 24 h before transfer into selection media (RPMI plus 2 mg/ml geneticin). In all experiments, bulk FACS-sorted transfectants were tested. For transient transfections, 2ϫ10 7 Jurkat cells/well were transfected as described above and resuspended in 10 ml RPMI complete medium for 24 h before stimulation.
mAb and reagents
The following mAb were used in these studies: 2E11, 2D3 [IgG1, murine anti-huIAP (16, 22) Flow cytometry Cells were stained with saturating concentrations of antibody, then incubated with fluorescein-conjugated goat anti-mouse or goat anti-rat antibody before analysis in a FACScan (Epics XL; Coulter) as previously described (16) .
Preparation of antibody-coated tissue culture plates
Plates were coated as previously described. Briefly, flatbottomed microtiter (3595; Costar, Cambridge, MA) and sixwell plates (3046; Becton Dickinson Labware, Franklin Lakes, NY) were precoated overnight at 4°C with 5 µg/ml goat antimouse IgG antibodies (Organon Teknika, Durham, NC) (70 µl/ well or 2 ml/well) in 20 mM sodium bicarbonate buffer, pH 9.0. Additional protein binding sites were blocked by treatment with 2% BSA overnight in RPMI 1640 at 4°C. After washing plates for 3 times with PBS, the individual stimulating antibodies were added in a 100 µl or 1 ml volume (final volume per well was 200 µl or 2 ml) and incubated overnight at 4°C. OKT3 supernatant was used in 10-fold dilutions. All other antibodies were used at 1 µg/ml or as indicated.
Production of IL-2 IL-2 production was measured by incorporation of [ 3 H]-thymidine (0.4 µCi/well, 6.7 Ci/mmol sp. act.; ICN) by CTLL-2 cells as previously described (11) .
Cell spreading
Jurkat cells were resuspended at 2.5ϫ10 5 cells/ml in RPMI-CM and allowed to spread on mAb-coated tissue culture wells for 2-5 h at 37°C in 5% CO 2 .
Luciferase assay
Jurkat cells were stimulated on antibody-coated plates for 6 h at 24 h after transfection. Following stimulation, the cells were washed 3 times with PBS and resuspended in 1 ml TEN buffer [40 mM Tris (pH 7.8), 1 mM EDTA, 150 mM NaCl], centrifuged, resuspended in 150 µl of 250 mM Tris (pH 8.0) and freezethawed 3 times (dry ice to 37°C bath). Cell debris were removed by centrifugation at top speed in a microfuge tube and 75 µl of the cleared extract was measured using an Optocomp II (MGM) Luminometer.
Preparation of total cell lysates and extracellular-signalregulated (ERK) mobility shift Jurkat cells (5ϫ10 6 ) were applied to antibody-coated plates and incubated at 37°C for the times indicated in the text. Cells were then lysed in 500 µl ice cold lysis buffer [50 mM HEPES (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 1 mM H 2 O 2 -activated Na 3 VO 4 , 50 mM NaF, 1 mM p-nitrophenyl phosphate, 50 nM calyculin A, 1 mM PMSF, and 10 µg/ml aprotinin and leupeptin] and insoluble material was removed by centrifugation at 13,000 g for 5 min. Then 50 µl of lysate was electrophoresed on a 15% SDSpolyacrylamide gel, blotted onto nitrocellulose and incubated with 0.2 µg/ml anti-ERK mAb. The antibody-antigen complexes were visualized by enhanced chemiluminescence (Pierce, Rockford, IL).
Solid-phase JNK assay and immunoblot
The solid-phase JNK assay was performed using a kit according to the manufacturer's instructions (New England Biolab, Beverly, MA). Briefly, 2ϫ10 6 cells/well were lysed with cell lysis buffer [20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM Na pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 µg/ml leupeptin and 1 mM PMSF]. The cell extracts were mixed with 2 µg of c-Jun fusion protein beads and incubated with gentle rocking overnight at 4°C. Pellets were washed twice with 500 µl lysis buffer and twice with 500 µl kinase buffer [25 mM Tris (pH 7.5), 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na 3 VO 4 and 10 mM MgCl 2 ] and suspended in 50 µl kinase buffer containing 100 µM ATP. After 30 min at 30°C the reaction was stopped by the addition of 20 µl 3ϫSDS sample buffer. Phosphorylated proteins were resolved on a 15% SDS-polyacrylamide gel, transferred to nitrocellulose membranes and incubated with a 1:1000 dilution of rabbit polyclonal phospho-specific c-Jun (Ser63) antibody. Detection of the protein-antibody complexes was done as described above. Before addition of the primary antibody, membranes were stained with Coomassie blue to confirm equal loading of sample in each lane.
Results
IAP co-stimulation requires the TCR complex
We recently have shown that IAP can enhance T cell activation in conjunction with suboptimal anti-CD3. To further study the interaction between TCR and IAP in this synergy, we transfected Jurkat cells with a chimeric molecule consisting of the extracellular domain of CD16 (FcγRIII, an irrelevant Ig family member), the transmembrane domain of CD7 and the TCR ζ chain cytoplasmic tail (CD16-7-ζ) (26) . Aggregation of this construct leads to its tyrosine phosphorylation, and to cell activation events such as increased [Ca 2ϩ ] i and cytotoxicity (26 and data not shown). Surprisingly, Jurkat cells transfected with the CD16-7-ζ chimera failed to produce significant levels of IL-2 at all concentrations of anti-CD16 tested (Fig. 1A) . Furthermore, none of the anti-IAP mAb was able to co-stimulate IL-2 production with cross-linking of the CD16 chimera. In contrast, anti-CD28 co-stimulated very efficiently (Fig. 1A) . In these same CD16-7-ζ transfected cells, all anti-IAP mAb tested enhanced IL-2 production in conjunction with suboptimal anti-CD3 mAb (Fig. 1B) . These data show that IAP is unable to co-stimulate IL-2 production in conjunction with the incomplete TCR signal furnished by the CD16-7-ζ chimera. To confirm this result, we transiently transfected Jurkat cells with an IL-2-LUC reporter, containing the regulatory region of the IL-2 gene fused to the luciferase (LUC) reporter gene (27) . Ligation of IAP with plate-bound mAb synergized with low concentrations of anti-CD3 to upregulate IL-2 transcription, demonstrating that transcriptional activation of the IL-2 gene is involved in IAP synergy with TCR ( Fig. 2A) . The level of induction mediated by suboptimal anti-CD3 plus anti-IAP was similar to that seen for high concentrations of anti-CD3 ( Fig. 2A) . As with IL-2 synthesis, no enhancement of IL-2 transcription was observed at any concentration of anti-CD16 mAb tested and no anti-IAP mAb could synergize with anti-CD16 to induce IL-2 transcription, whereas anti-CD28 mAb did so efficiently (Fig. 2B) . These experiments support the model that IAP's role is to enhance the efficiency of productive ligation of the TCR complex. In contrast, CD28's mechanism of action is distinct, since it can efficiently enhance IL-2 transcription and synthesis together with CD16-7-ζ. 
IAP synergizes with TCR but not CD16-7-ζ to activate ERK kinase
To define the reason for the inability of IAP to synergize with CD16-7-ζ, we compared the signaling pathway induced by co-ligation of the TCR complex or CD16-7-ζ with both IAP and CD28. First, we determined the ability of IAP and CD28 to augment ERK activation, which is required for IL-2 transcription and synthesis (28) . ERK activation was measured by retardation of migration on SDS-PAGE, reflecting increased phosphorylation, as previously described (29) . mAb against IAP and CD28 both synergized with low-concentration anti-CD3 to activate ERK, as compared to the negative control mAb (Fig. 3A) . Adhesion to either anti-IAP or anti-CD28 mAb alone did not enhance ERK activation (data not shown). No enhancement of ERK activation by cell adhesion to anti-IAP was seen in conjunction with a suboptimal concentration of anti-CD16 mAb (Fig. 3B) , whereas anti-CD28 mAb 9.3 efficiently co-stimulated ERK activation (Fig. 3B) . Importantly, coating plates with a high concentration of either anti-CD3 or anti-CD16 induced activation of ERK kinases without ligation of either CD28 or IAP (Fig. 3A and B) . This differs from the induction of IL-2 transcription and synthesis, where anti-CD16 was inactive at any concentration. Thus, although IAP can co-stimulate ERK activation with suboptimal anti-CD3, ERK activation alone is insufficient to initiate IL-2 synthesis.
Synergistic activation of JNK by anti-CD3 and anti-IAP Recently, JNK has been identified as a distinct member of the MAP kinase group (30) . This kinase selectively phosphorylates the N-terminal transactivating domain of the c-Jun protein, thereby increasing its transcriptional activity and ultimately leading to enhanced IL-2 synthesis. Experiments by Su et al. (27) showed that activation of JNK is dependent on the integration of at least two signals. In model systems, these signals have been generated either by treatment with phorbol ester and ionomycin or by cross-linking with anti-CD3 and anti-CD28 mAb. To determine whether IAP ligation synergizes with TCR in JNK activation, we measured the phosphorylation of Gst-c-Jun by lysates of cells adherent to various surfaces. Both anti-IAP mAb and anti-CD28 mAb efficiently augmented JNK activation with suboptimal anti-CD3 (Fig. 4A) . Adhesion of Jurkat cells to plates coated with high-concentration anti-CD3 alone also activated JNK (data not shown). In contrast, anti-CD16 failed to activate JNK without co-stimulation at any concentration tested (Fig. 4B and data not shown) . However, ligation with high-or low-concentration anti-CD16 in the presence of anti-CD28 mAb efficiently activated JNK (Fig. 4B and data not shown). Co-ligation of CD16 and IAP did not cause JNK activation (Fig. 4B) . These data suggest that activation of JNK requires signals mediated by the TCR complex which cannot be generated by the CD16-7-ζ construct. These signals are provided by co-stimulation with anti-CD28, which has been shown to be involved in JNK activation (27) , but are not provided by co-ligation of IAP.
Anti-IAP mAb induces Jurkat cell spreading
One difference between IAP and CD28 in T cell activation is that while CD28 and TCR can be engaged on opposite cell surfaces, IAP synergy requires ligation on the antigenpresenting surface (11) . A further difference between these two activation stimuli is the ability of IAP, but not CD28, to augment early signaling events arising from TCR ligation (11) . Together with IAP's inability to enhance IL-2 production in conjunction with the incomplete TCR signal provided by CD16-7-ζ, these findings suggest that IAP's role could be to increase the efficiency of the TCR signal, perhaps by increas- Cell lysates were incubated with 2 µg Gst-c-Jun (1-89) agarose beads for 12 h at 4°C. After extensive washing, the beads were incubated in kinase buffer for 30 min at 30°C, after which proteins were separated by SDS-PAGE followed by Western blotting with phospho-specific c-jun (Ser63) antibody. (B) Jurkat clones transfected with CD16-7-ζ were stimulated for 30 min at 37°C with a high concentration of anti-CD16 (5 µg/ml) or a low concentration of anti-CD16 (0.05 µg/ml) co-immobilized with anti-CD28, anti-IAP or control (MOPC) mAb. Cells were treated for 15 min at 37°C with 50 µg/ml phorbol myristate acetate and 1 mM ionomycin for positive control. Activation of JNK kinase activity was analyzed as described in (A). Experiments shown are representative of more than three with similar results.
ing effective ligation of the TCR complex by suboptimal ligand. For this reason we investigated if ligation of IAP on Jurkat cells induced cell spreading, since increased cell area in contact with ligand could enhance presentation to TCR. Jurkat cells were allowed to adhere to plates coated with anti-IAP (2E11, 2D3, B6H12 or 2B7), anti-CD28 (9.3) or control (W6/ 32; IB4) mAb, either with or without co-immobilized lowconcentration anti-CD3 (OKT3) mAb, as used for synergistic signaling. Following incubation at 37°C for 2-5 h, a dramatic increase in spreading was observed in the anti-IAP-coated wells as compared to anti-CD28 or control mAb ( Fig. 5 ; data not shown). This spreading is independent of the TCR complex and its signal, since it occurred in the absence of activation via anti-CD3 mAb (Fig. 5) , and in Jurkat cells which do not express the TCR complex (not shown). The tyrosine kinase lck also was not required for spreading, since Jurkat cells deficient in lck (J. Caml) (31) spread normally on anti-IAP mAb-coated surfaces (data not shown). Treatment of cells with 2 mM EGTA or EDTA did not inhibit spreading induced by anti-IAP mAb (data not shown), suggesting that it is not mediated by integrin-ligand interactions nor dependent on extracellular Ca 2ϩ . Spreading was completely inhibited by cytocholasin D at 5 µg/ml (data not shown), demonstrating a role for the actin cytoskeleton in Jurkat cell spreading on anti-IAP. The IAP extracellular and transmembrane domains are required for spreading of Jurkat cells
To determine which domain(s) of IAP were required for spreading we utilized an IAP-deficient Jurkat cell line, which was generated by chemical mutagenesis (see Methods). An IAP-deficient subclone of these cells, JinB8, was used for subsequent studies. This clone expressed no IAP by FACS analysis (Fig. 6) . Expression levels of other cell surface molecules, such as MHC class I (W6/32) or the β 2 integrin (IB4), were not affected (Fig. 6) . Expression level of the TCR complex declined when the clones were maintained in culture for an extended period of time and transfection of these cells with IAP did not stabilize cell surface expression of TCR (data not shown). All cells were sorted for high levels of CD3 expression prior to analysis (Fig. 6 ). JinB8 cells were transfected with wild-type human IAP (huIAP form 2), huIAP form 1, which has only 4 amino acids in its cytoplasmic tail, and huIAP/CD7, which consists of the IAP extracellular domain anchored into the membrane via the CD7 transmembrane domain (see Fig. 7A ). Expression levels of the transfected constructs were similar as determined by FACS staining (Fig.  7B) . Transfection of this clone with the expression vector alone failed to generate IAP ϩ cells, confirming that the IAP expressed in the transfectants was a product of the input DNA. Anti-IAP mAb 2E11 and 2D3 synergized with suboptimal concentrations of anti-CD3 to enhance IL-2 synthesis in cells transfected with huIAP form 1 and form 2, but not in cells transfected with the huIAP-CD7 construct (Table 1 and data not shown). These data are entirely consistent with the structure-function studies previously reported for human IAP transfected into the murine 3L2 T cell hybridoma (11) .
When JinB8 cells expressing huIAP form 1 or form 2 adhered to plates coated with anti-IAP mAb [2E11 (Fig. 8A ), 2B7 and B6H12 (not shown)] with or without anti-CD3, they were able to spread. No spreading was observed on plates coated with anti-CD28 [9.3 (Fig. 8B) or anti-MHC class I (not shown) mAb] with or without anti-CD3. In contrast, JinB8 cells transfected with huIAP/CD7 did not spread on anti-IAP mAb (Fig. 8C ) with or without anti-CD3. Similarly, Jurkat cells transfected with FLAG-TM2, a chimeric molecule in which the entire IAP extracellular domain was replaced by the FLAG epitope (Fig. 7) , were unable to spread when allowed to adhere to plates coated with anti-FLAG mAb (Fig. 8F) , whether or not anti-CD3 was co-immobilized. Furthermore, no IL-2 synthesis was observed when these same transfected Jurkat clones were allowed to adhere to plates coated with sub- optimal anti-CD3 plus anti-FLAG mAb (Table 1) . These Jurkat transfectants could still respond to anti-IAP (Table 1 ). The FLAG epitope was accessible to the antibody, as shown by FACS (Fig. 7B) . These data show that both the IAP extracellular and transmembrane domains are required for spreading, while the cytoplasmic tail is dispensable. Thus, the domains required for IAP's ability to induce cell spreading and to enhance IL-2 production (11) ( Table 1) with suboptimal anti-CD3 were identical, suggesting a close correlation between IAP's ability to induce cell spreading and its synergy with TCR. These data suggest the hypothesis that the main effect of IAP ligation is to increase the frequency of productive ligation of the TCR by increasing T cell spreading on the antigen-presenting surface.
Discussion
Full activation of T cells requires the participation of accessory or co-stimulatory molecules. Recently, we have shown that IAP can function to augment T cell activation (11) . In recent years, much has been learned about the signal mediated by the TCR. In contrast, the mechanisms by which co-stimulators function, as well as their signaling pathways, are still poorly understood. This is true even of CD28, the most extensively studied co-stimulator to date. The object of the present study was to further analyze the role of IAP in T cell activation and to determine its relationship to CD28 and TCR signals.
Detailed analysis of signaling events showed that IAP enhances IL-2 production in the presence of low concentrations of anti-CD3 by activation of the MAP kinases ERK1/2 and JNK, resulting in increased IL-2 transcription. Unlike CD28, which has identical biochemical effects, IAP may augment activation by increasing the efficiency of antigen receptor signaling. Supporting this hypothesis is (i) IAP costimulation of early events in TCR signaling (11), (ii) IAP conversion of antagonist to agonist peptides (11) , suggesting an enhancement of signal strength (a property not shared by CD28), and (iii) as demonstrated in this study, the inability of IAP, unlike CD28, to generate new signals when co-ligated with CD16-7-ζ. A possible mechanism by which IAP ligation may enhance the efficiency of antigen receptor activation is suggested by the discovery that Jurkat cells will spread on a surface coated with anti-IAP. When the surface is coated with anti-CD3 as well, it is likely that increased CD3 engagement will occur either because the cell surface in contact with the activating ligand is increased or because adhesion to the activating surface is tighter. On an appropriate antigenpresenting cell (APC), ligand for IAP also could induce an increased interaction between T cell and APC. Actin filamentdependent spreading induced by IAP ligation could prolong the time of contact between individual TCR molecules and the MHC-peptide complex on the APC as well as the number of contacts attained. In its ability to induce cell spreading, IAP ligation differs dramatically from CD28, which co-stimulates without causing cell spreading. It may be that IAP shares this mechanism of action with other adhesion-dependent accessory molecules, such as LFA-1 or integrin extracellular matrix receptors (10, 32, 33) .
To test this hypothesis, we determined which IAP domains were required for Jurkat spreading. A previous study had demonstrated a requirement for both the Ig and the multiply membrane-spanning domain of IAP in T cell activation (11). If spreading on the antigen-coated surface was important in synergy with TCR, the same domains should be required for spreading. Indeed, our structure-function studies on IAP demonstrated a requirement for both the extracellular IgV and the multiply membrane-spanning domains for cell spreading, without need for the IAP cytoplasmic tail, providing a link JinB8 and Jurkat cell transfectants were tested for IL-2 synthesis when allowed to adhere to plates coated with anti-CD3 lo (1) with or without anti-IAP (2E11), control (W6/32) or anti-FLAG (M2) mAb. Experimental conditions are as in Fig. 1 between spreading and IAP-TCR synergy. The fact that TCRdeficient Jurkat cells spread on anti-IAP-coated plates and that normal Jurkat cells do not spread on the low concentrations of anti-CD3 used in these experiments rules out an essential role for the TCR in IAP-mediated cell spreading. The requirement for the IAP multiply membrane-spanning domain in cell spreading suggests that it may mediate contacts with cytosolic or other membrane proteins to signal actin filament assembly. How this occurs is not yet known. While interaction with lymphocyte integrins is an appealing hypothesis, failure of divalent cation chelators to affect IAPdependent spreading does not support this model.
The requirement for the Ig domain of IAP in spreading is quite surprising, since this domain is separated from the cytoskeleton by a plasma membrane. The only known roles for the IAP Ig domain are in binding thrombospondin (34) and in lateral interaction with α v integrins (19) . The requirement for the Ig domain in both T cell activation and spreading suggests either that there are additional unknown lateral interactions of the IAP Ig domain or that the Ig domain is required for appropriate conformation and cytoskeletal association of the multiply membrane-spanning domain. Further work will be required to distinguish these possibilities.
The TCR complex is composed of six different polypeptide chains, including a ligand binding heterodimer (αβ or γδ) and the non-polymorphic CD3 (ε, γ, δ) and ζ chains. The complexity of the TCR may be means for amplifying the TCR signal (35) , since chimeric molecules containing a single functional domain of ζ are sufficient, although less potent, to induce signaling (36) . Why the CD16-7-ζ construct used in this study does not enhance IL-2 production is uncertain. It is possible that, since this construct exists as a monomer on the cell surface, whereas the TCR ζ chain naturally exists as a dimer, it fails to generate a fully activating signal because of differences in antibody-induced clustering. Chimeras in which the ζ chain has been linked to the CD8 or IL-2 receptor extracellular and transmembrane domains do form dimers and are able to induce IL-2 production after antibody crosslinking, albeit less efficiently than the TCR complex (37, 38) . An alternative explanation for the failure of CD16-7-ζ crosslinking to signal IL-2 transcription may be that ITAMs are bound differentially by different signaling molecules, such as Zap70, phospholipase Cγ1 or shc (36, 39, 40) and that some essential component is not recruited by cross-linking the chimeric receptor. Whatever its basis, the finding that activation with high concentrations of anti-CD16 mAb did not activate JNK or induce IL-2 production provided a mechanism for further distinguishing the adhesion-dependent effect of IAP on T cell activation from CD28.
The defect in signaling from the CD16-7-ζ chimera is its inability to activate JNK, which presumably leads to failure to activate c-Jun and therefore to form the AP-1 transcription complex which is required for IL-2 transcription. Our data clearly demonstrate that co-ligation of CD28 provides a sufficient signal for JNK activation by CD16-7-ζ, while coligation of IAP does not. An essential role for CD28 in costimulation of JNK has been suggested previously (27) . Importantly, cross-linking of CD28 alone does not activate JNK, so signals from ligation of the chimeric ζ chain receptor are clearly required for this activation. This is consistent with the model that JNK is involved in the integration of TCR and CD28 signals during T cell activation, leading to enhanced IL-2 production (27) . Furthermore, the ability of CD28 to synergize with the chimeric construct shows that co-stimulation with CD28 imparts new signaling activities to cross-linked CD16-7-ζ rather than simply enhancing the efficiency of the signaling from the chimeric molecule, a property which further distinguishes the mechanism of co-stimulation by IAP and CD28. It is possible that upon IAP ligation, IAP associates with specific signaling molecules or regulators of cytoskeletal organization. These proteins may then be able to relay the signal into the cell, resulting in cytoskeletal reorganization. In support of this hypothesis is the observation that IAP has been found to associate with a src kinase family member (12) and Gα subunits (41) . However, as proven by the failure of IAP to co-stimulate the CD16-7-ζ chimera, any putative IAPderived signals cannot contribute directly to the T cell mitogenic pathway.
In summary, a detailed study of the pathways arising from ligation of IAP or CD28 with TCR demonstrates that they differ in several fundamental aspects. CD28 can costimulate IL-2 synthesis together with a CD16-7-ζ chimera, while IAP cannot, suggesting that CD28 has an ability to complement the ζ chain signal not shared by IAP. In contrast, IAP augments early events in T cell activation and induces cell spreading, properties not shared by CD28. These data are completely consistent with the hypothesis that IAP ligation induces increased T cell contact with an antigen-presenting surface but that the mitogenic signal arises entirely from TCR ligation. Thus, unlike CD28, IAP can increase the sensitivity of even the earliest events to suboptimal TCR ligation. On the other hand, ligation of IAP and TCR cannot reconstitute a mitogenic signal from a signaling-deficient TCR. It will be important to determine by examining other adhesion-dependent co-activators such as ICAM-1, fibronectin and collagen, whether this difference between IAP and CD28 is the fundamental distinction between those co-stimulators that act by enhancing adhesion and those that generate TCR-independent signals.
